Jon Ukropec

4.2k citations

44 papers · 1.2k indexed · h-index 17

Impact in

Hematology top 1%
- Multiple Myeloma Research and Treatments
- Chronic Myeloid Leukemia Treatments
Oncology top 5%
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
- CAR-T cell therapy research

Papers in ⓘ

Hematology 39
- Multiple Myeloma Research and Treatments 37
- Chronic Myeloid Leukemia Treatments 7
Oncology 20
- Peptidase Inhibition and Analysis 14
- Cancer Treatment and Pharmacology 4

Co-authors: Meletios Α. Dimopoulos (11 shared papers)Nizar J. Bahlis (8 shared papers)Ming Qi (20 shared papers)Sarah Côté (4 shared papers)Jianming He (2 shared papers)Annette Lam (5 shared papers)Lotfi Benboubker (5 shared papers)Xiang Qin (5 shared papers)
Journals: Blood (19 papers)Journal of Clinical Oncology (5 papers)Leukemia (2 papers)Blood Advances (2 papers)Cancer (1 paper)
Partner nations: United States Spain France

In The Last Decade

Jon Ukropec

41 papers receiving 1.1k citations

Peers

Countries citing papers authored by Jon Ukropec

Since Specialization

Citations

This map shows the geographic impact of Jon Ukropec's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jon Ukropec with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jon Ukropec more than expected).

Fields of papers citing papers by Jon Ukropec

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jon Ukropec. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jon Ukropec. The network helps show where Jon Ukropec may publish in the future.

Co-authors

The 25 scholars most cited alongside Jon Ukropec, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jon Ukropec Line = papers co-authored together Jon Ukropec links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 44 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma Blood Advances ·Nikhil C. Munshi, Hervé Avet‐Loiseau, Kenneth C. Anderson, Paola Neri, Bruno Paiva, Mehmet Samur, Meletios Α. Dimopoulos, Margarita Kulakova, Annette Lam, Mahmoud Hashim, Jianming He, Bart Heeg, Jon Ukropec, Jessica Vermeulen, Sarah Côté, Nizar J. Bahlis	2020	226
2	Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study Leukemia ·Nizar J. Bahlis, Meletios Α. Dimopoulos, Darrell White, Lotfi Benboubker, Gordon Cook, Merav Leiba, P. Joy Ho, Kihyun Kım, Naoki Takezako, Philippe Moreau, Jonathan L. Kaufman, Maria Krevvata, Christopher Chiu, Xiang Qin, Linda Okonkwo, Sonali Trivedi, Jon Ukropec, Ming Qi, Jesús F. San Miguel	2020	158
3	Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma Blood ·Ajai Chari, Joaquín Martínez‐López, María‐Victoria Mateos, Joan Bladé, Lotfi Benboubker, Albert Oriol, Bertrand Arnulf, Paula Rodríguez‐Otero, Luis Piñeiro, Andrzej Jakubowiak, Carla de Boer, Jianping Wang, Pamela L. Clemens, Jon Ukropec, Jordan M. Schecter, Sagar Lonial, Philippe Moreau	2019	101
4	Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR Clinical Lymphoma Myeloma & Leukemia ·María‐Victoria Mateos, Pieter Sonneveld, Vânia Hungria, Ajay K. Nooka, Jane Estell, Wolney Barreto, Paolo Corradini, Chang‐Ki Min, Eva Medvedova, Katja Weisel, Christopher Chiu, Jordan M. Schecter, Himal Amin, Xiang Qin, Jon Ukropec, Rachel Kobos, Andrew Spencer	2019	93
5	Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma BMC Cancer ·Rafaël Fonseca, Saad Z. Usmani, Maneesha Mehra, Mary Slavcev, Jianming He, Sarah Côté, Annette Lam, Jon Ukropec, Eric M. Maiese, Sandhya Nair, Ravi Potluri, Peter M. Voorhees	2020	67
6	BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase Leukemia ·Timothy P. Hughes, Giuseppe Saglio, Alfonso Quintás‐Cardama, Michael J. Mauro, D-W Kim, Jeffrey H. Lipton, M. Brigid Bradley‐Garelik, Jon Ukropec, Andreas Hochhaus	2015	52
7	Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study British Journal of Haematology ·Habte Yimer, Jason M. Melear, Edward A. Faber, William Bensinger, John M. Burke, Mohit Narang, Don A. Stevens, Sriya Gunawardena, Yana Lutska, Keqin Qi, Jon Ukropec, Ming Qi, Thomas S. Lin, Robert M. Rifkin	2019	49
8	Cardiovascular and pulmonary adverse events in patients treated with BCR‐ABL inhibitors: Data from the FDA Adverse Event Reporting System American Journal of Hematology ·Jörge E. Cortes, Michael J. Mauro, Juan Luis Steegmann, Giuseppe Saglio, Rachpal Malhotra, Jon Ukropec, Nicola Wallis	2015	44
9	Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies Haematologica ·María‐Victoria Mateos, Andrew Spencer, Ajay K. Nooka, Luděk Pour, Katja Weisel, Michèle Cavo, Jacob P. Laubach, Gordon Cook, Shinsuke Iida, Lotfi Benboubker, Saad Z. Usmani, Sung‐Soo Yoon, Nizar J. Bahlis, Christopher Chiu, Jon Ukropec, Jordan M. Schecter, Xiang Qin, Lisa O’Rourke, Meletios Α. Dimopoulos	2019	43
10	Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from Griffin, a Phase 2 Randomized Study of Daratumumab (Dara), Bortezomib (V), Lenalidomide (R), and Dexamethasone (D; Dara‐Vrd) Vs. Vrd in Patients (Pts) with Newly Diagnosed (ND) Multiple Myeloma (MM) Eligible for High‐Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT) Blood ·Peter M. Voorhees, Cesar Rodriguez, Brandi Reeves, Nitya Nathwani, Luciano J. Costa, Yana Lutska, Daniela Hoehn, Huiling Pei, Jon Ukropec, Ming Qi, Thomas S. Lin, Paul G. Richardson	2018	32
11	Use of Montelukast to Reduce Infusion Reactions in an Early Access Treatment Protocol of Daratumumab in United States Patients with Relapsed or Refractory Multiple Myeloma Blood ·Ajai Chari, Tomer M. Mark, Amrita Krishnan, Keith Stockerl‐Goldstein, Saad Z. Usmani, Anil Londhe, Delores Etheredge, Hollee Parros, Sarah Fleming, Baolian Liu, Sara M. Freeman, Jon Ukropec, Thomas S. Lin, Ajay K. Nooka	2016	31
12	Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM) Blood ·Jonathan L. Kaufman, Saad Z. Usmani, Jesús F. San Miguel, Nizar J. Bahlis, Darrell White, Lotfi Benboubker, Gordon Cook, Merav Leiba, P. Joy Ho, Kihyun Kım, Naoki Takezako, Philippe Moreau, Maria Krevvata, Huiling Pei, Jon Ukropec, Thomas Renaud, Sonali Trivedi, Rachel Kobos, Meletios Α. Dimopoulos	2019	28
13	Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma Cancer ·Ajai Chari, Sagar Lonial, Tomer M. Mark, Amrita Krishnan, Keith Stockerl‐Goldstein, Saad Z. Usmani, Anil Londhe, Delores Etheredge, Sarah Fleming, Baolian Liu, Jon Ukropec, Thomas S. Lin, Sundar Jagannath, Ajay K. Nooka	2018	27
14	Early Response (Molecular and Cytogenetic) and Long-Term Outcomes in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Analysis of DASISION 3-Year Data Blood ·Giuseppe Saglio, Hagop M. Kantarjian, Neil P. Shah, Elias Jabbour, Alfonso Quintás‐Cardama, Juan Luis Steegmann, Concepción Boqué, Charles Chuah, Carolina Pavlovsky, Jiřı́ Mayer, Jon Ukropec, Mark Wildgust, Andreas Hochhaus	2012	27
15	Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients (pts) with Multiple Myeloma (MM): Four-Year Update of Castor Blood ·Katja Weisel, Pieter Sonneveld, María‐Victoria Mateos, Vânia Hungria, Andrew Spencer, Jane Estell, Wolney Barreto, Paolo Corradini, Chang‐Ki Min, Eva Medvedova, Maria Krevvata, Sonali Trivedi, Xiang Qin, Huiling Pei, Jon Ukropec, Rachel Kobos, Ming Qi, Ajay K. Nooka	2019	26
16	Updated risk stratification model for smoldering multiple myeloma (SMM) incorporating the revised IMWG diagnostic criteria. Journal of Clinical Oncology ·Jesús F. San Miguel, María‐Victoria Mateos, Verónica González, Meletios Α. Dimopoulos, Efstathios Kastritis, Roman Hájek, Carlos Fernández de Larrea Rodríguez, Gareth J. Morgan, Giampaolo Merlini, Silvia Mangiacavalli, Hartmut Goldschmidt, Michèle Cavo, Charalampia Kyriakou, Ming Qi, Jon Ukropec, Brendan M. Weiss, Chris Cameron, S. Vincent Rajkumar, Brian G.M. Durie, Shaji Kumar	2019	19
17	Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN Blood Advances ·Peter M. Voorhees, Cesar Rodriguez, Brandi Reeves, Nitya Nathwani, Luciano J. Costa, Yana Lutska, Padma Bobba, Daniela Hoehn, Huiling Pei, Jon Ukropec, Ming Qi, Thomas S. Lin, Paul G. Richardson	2021	18
18	Evaluation of Sustained Minimal Residual Disease (MRD) Negativity in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone (D-Rd) or Bortezomib Plus Dexamethasone (D-Vd): Analysis of Pollux and Castor Blood ·Hervé Avet‐Loiseau, Jesús F. San Miguel, Tineke Casneuf, Shinsuke Iida, Sagar Lonial, Saad Z. Usmani, Andrew Spencer, Philippe Moreau, Torben Plesner, Katja Weisel, Jon Ukropec, Linda Okonkwo, Sonali Trivedi, Christopher Joseph Velas, Xiang Qin, Ming Qi, Christopher Chiu, Nizar J. Bahlis	2018	14
19	Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses Advances in Therapy ·Xu Steven Xu, Philippe Moreau, Saad Z. Usmani, Sagar Lonial, Andrzej Jakubowiak, Albert Oriol, Amrita Krishnan, Joan Bladé, Man Luo, Yu‐Nien Sun, Honghui Zhou, Ivo Nnane, William Deraedt, Ming Qi, Jon Ukropec, Pamela L. Clemens	2020	9
20	Daratumumab (DARA) Maintenance Therapy Improves Depth of Response and Results in Durable Progression-Free Survival (PFS) Following Dara Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Therapy in Multiple Myeloma (MM): Update of the Lyra Study Blood ·Robert M. Rifkin, Jason M. Melear, Edward A. Faber, William Bensinger, John M. Burke, Mohit Narang, Don A. Stevens, Sriya Gunawardena, Yana Lutska, Keqin Qi, Jon Ukropec, Ming Qi, Thomas S. Lin, Habte Yimer	2019	9

About Jon Ukropec

Jon Ukropec is a scholar working on Hematology, Oncology, Molecular Biology, Organic Chemistry and Genetics, having authored 44 papers that have together received 1.2k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (37 papers), Peptidase Inhibition and Analysis (14 papers), Synthesis and Biological Evaluation (12 papers), Protein Degradation and Inhibitors (10 papers), Chronic Lymphocytic Leukemia Research (10 papers), Chronic Myeloid Leukemia Treatments (7 papers), Lymphoma Diagnosis and Treatment (4 papers) and Cancer Treatment and Pharmacology (4 papers). The work is most often cited by research in Hematology (1.1k citations), Oncology (665 citations), Genetics (198 citations), Molecular Biology (731 citations) and Radiology, Nuclear Medicine and Imaging (95 citations). Jon Ukropec has collaborated with scholars based in United States, Spain and France. Frequent co-authors include Meletios Α. Dimopoulos, Nizar J. Bahlis, Ming Qi, Sarah Côté, Jianming He, Annette Lam, Lotfi Benboubker, Xiang Qin, Philippe Moreau and María‐Victoria Mateos. Their work appears in journals such as Blood, Journal of Clinical Oncology, Leukemia, Blood Advances and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact